Convalescent Plasma Therapy for COVID-19 Patients
Experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection is the focus of a new two-part research initiative.
Read moreCRISPR-engineered T cells in Patients with Refractory Cancer
Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published in Science by researchers from the Abramson Cancer Center.
Read moreCRISPR-engineered T cells in patients with refractory cancer
Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Abramson Cancer Center.
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
An image from this article is featured on the cover of this edition of Blood Advances, a semimonthly medical journal published by the American Society of Hematology. The cover figure of&
Read morePenn's Gene Therapy Startup Raises Another $50 Million
Funding for cellular therapies that target specific B cells that mediate a wide variety of autoimmune conditions.
Read moreNational Blood Foundation Early-Career Grant for Dr. Vijay Bhoj
Award for research in the fields of transfusion medicine and cellular therapies.
Read more
